By vgreene, 16 September, 2021 Convalescent Plasma for Hospitalized Patients With COVID 19 An Open label Randomized Controlled Trial CONCOR 1
By vgreene, 16 September, 2021 Study considerations meta analysis incl 24 randomized trials some open label many not peer reviewed studies small and varied in dosage tx duration inclusion criteria outcomes measures other tx comparators among studies varied most trials in mild moderate
By vgreene, 16 September, 2021 KEY FINDINGS ivermectin reduces inflammatory markers achieves viral clearance more quickly and improves survival vs SOC in mild moderate dz no significant differences on survival in severe dz
By vgreene, 16 September, 2021 Note One of the studies included in the meta analysis has been withdrawn due to fraudulent data Authors will be submitting a revised version of the meta analysis excluding that study
By vgreene, 16 September, 2021 Meta analysis of Randomized Trials of Ivermectin to Treat SARS CoV 2 Infection RETRACTED 8 9 21 pending revision
By vgreene, 16 September, 2021 Study considerations 15 RCTs included for primary outcome 3 RCTs included for prophylaxis 10 trials reported adequate blinding preprint and unpublished data included assessing risk of bias challenging
By vgreene, 16 September, 2021 KEY FINDINGS ivermectin reduced risk of death based on moderate certainty evidence ivermectin prophylaxis reduced infection by 86 based on low certainty evidence
By vgreene, 16 September, 2021 Ivermectin for Prevention and Treatment of COVID 19 Infection A Systematic Review Meta analysis and Trial Sequential Analysis to Inform Clinical Guidelines
